A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer

Figures & data

Table 1. Clinical characteristics of the study population.

	Number (%)
Gender
Male	11 (73%)
Female	4 (27%)
Age, years (median)	73
Prior tumour occurrences
1–2	9 (60%)
≥3	2 (13%)
Prior intravesical therapy
MMC^1	4 (27%)
BCG^2	7 (47%)
EORTC^3 recurrence score
High risk (score 10–17)	11 (73%)
Intermediate risk (score 5–9)	4 (27%)
Tumour grade
Low grade	10 (67%)
High grade	5 (33%)
Associated CIS	2 (13%)
Tumour stage (TNM 2009)
Ta	9 (60%)
T1	6 (40%)
Large tumour burden
>50% bladder surface	4 (27%)

¹Mitomycin C

²Bacillus Calmette-Guérin

³European Organisation for Research and Treatment of Cancer [2].

Table 2. Adverse events of HIVEC.

	Number (%)
Genitourinary
Irritative lower urinary tract symptoms	5 (33%)
Bladder spasms	4 (27%)
Pain	4 (27%)
Haematuria	3 (20%)
Urinary tract infection	2 (13%)
Bladder calcification	1 (7%)
Low capacity bladder	1 (7%)
Allergic
MMC-induced skin rash	1 (7%)

Figure 1. CONSORT trials study diagram.

Figure 2. Cumulative incidence of bladder cancer recurrence.

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–75

 PubMed Web of Science ®Google Scholar